Component,Days to Follow Up,Adverse Event,Progression or Recurrence,Barretts Esophagus Goblet Cells Present,BMI,Cause of Response,Comorbidity,Comorbidity Method of Diagnosis,Days to Adverse Event,Days to Comorbidity,Diabetes Treatment Type,Disease Response,DLCO Ref Predictive Percent,ECOG Performance Status,FEV1 FVC Post Bronch Percent,FEV 1 FVC Pre Bronch Percent,FEV1 Ref Post Bronch Percent,FEV1 Ref Pre Bronch Percent,Height,Hepatitis Sustained Virological Response,HPV Positive Type,Karnofsky Performance Status,Menopause Status,Pancreatitis Onset Year,Reflux Treatment Type,Risk Factor,Risk Factor Treatment,Viral Hepatitis Serologies,Weight,Days to Progression,Days to Progression Free,Days to Recurrence,Progression or Recurrence Anatomic Site,Progression or Recurrence Type,entityId,HTAN Participant ID
FollowUp,73.0,,Not Reported,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,syn22249015,455.0
FollowUp,73.0,,Not Reported,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,syn22978975,461.0
